文献速递流行病学与生物统计真实世界研究与卫生经济

基于利益相关者偏好的疾病标志物与风险评分阳性阈值:方法学框架及在阻塞性肺疾病中的应用

Stakeholder-informed positivity thresholds for disease markers and risk scores: a methodological framework and an application in obstructive lung disease.
PubMed 文献 · J Clin Epidemiol · 2024-08-30

研究提出一个量化循证阳性阈值净获益的分析框架,结合偏好敏感参数与偏好无关参数,并用选择实验从利益相关者获取偏好权重。以阿奇霉素维持治疗慢性阻塞性肺疾病为例,477名受访者完成离散选择实验,使净获益最大化的12个月中度或重度急性加重风险阈值为≥12%。

要点

  • 框架整合偏好敏感参数与偏好无关参数以量化阳性阈值的净获益。
  • 阿奇霉素维持治疗案例中,12个月中度或重度急性加重风险≥12%时净获益最大。
  • 该利益相关者知情阈值显著低于现行指南中的隐含阈值。

核心结论

  • 所提方法学框架可应用于需要纳入利益相关者偏好的阳性阈值制定场景。
  • 应用于慢性阻塞性肺疾病药物治疗时,得到的利益相关者知情治疗阈值显著低于现行指南中的隐含阈值。

研究设计与样本

  • 提出基于偏好敏感参数与偏好无关参数量化阳性阈值净获益的分析框架。
  • 建议采用简约选择实验从利益相关者获取偏好敏感参数,并通过靶向证据合成量化偏好无关参数。
  • 以慢性阻塞性肺疾病阿奇霉素维持治疗为案例,用离散选择实验估计治疗相关属性水平的偏好权重。
  • 477名受访者完成了离散选择实验调查。

主要发现

  • 案例中,预防中度与重度急性加重(获益)以及听力损失和胃肠道症状风险(危害)成为重要属性。
  • 相对于每1%的重度急性加重风险,每1%中度急性加重风险、听力损失和胃肠道症状的偏好权重分别为0.395(95%CI 0.338-0.456)、1.180(95%CI 1.071-1.201)和0.253(95%CI 0.207-0.299)。
  • 使净获益最大化的最优阈值为治疗12个月中度或重度急性加重风险≥12%的患者。

关键数值与推荐

  • 每1%中度急性加重风险相对于每1%重度急性加重风险的偏好权重为0.395(95%CI 0.338-0.456)。
  • 每1%听力损失风险相对于每1%重度急性加重风险的偏好权重为1.180(95%CI 1.071-1.201)。
  • 每1%胃肠道症状风险相对于每1%重度急性加重风险的偏好权重为0.253(95%CI 0.207-0.299)。
  • 使净获益最大化的12个月中度或重度急性加重风险阈值为≥12%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A positivity threshold is often applied to markers or predicted risks to guide disease management. These thresholds are often decided exclusively by clinical experts despite being sensitive to the preferences of patients and general public as ultimate stakeholders. STUDY DESIGN AND SETTING: We propose an analytical framework for quantifying the net benefit (NB) of an evidence-based positivity threshold based on combining preference-sensitive (eg, how individuals weight benefits and harms of treatment) and preference-agnostic (eg, the magnitude of benefit and the risk of harm) parameters. We propose parsimonious choice experiments to elicit preference-sensitive parameters from stakeholders, and targeted evidence synthesis to quantify the value of preference-agnostic parameters. We apply this framework to maintenance of azithromycin therapy for chronic obstructive pulmonary disease using a discrete choice experiment to estimate preference weights for attribute level associated with treatment. We identify the positivity threshold on 12-month moderate or severe exacerbation risk that would maximize the NB of treatment in terms of severe exacerbations avoided. RESULTS: In the case study, the prevention of moderate and severe exacerbations (benefits) and the risk of hearing loss and gastrointestinal symptoms (harms) emerged as important attributes. Four hundred seventy seven respondents completed the discrete choice experiment survey. Relative to each percent risk of severe exacerbation, preference weights for each percent risk of moderate exacerbation, hearing loss, and gastrointestinal symptoms were 0.395 (95% confidence interval [CI] 0.338-0.456), 1.180 (95% CI 1.071-1.201), and 0.253 (95% CI 0.207-0.299), respectively. The optimal threshold that maximized NB was to treat patients with a 12-month risk of moderate or severe exacerbations ≥12%. CONCLUSION: The proposed methodology can be applied to many contexts where the objective is to devise positivity thresholds that need to incorporate stakeholder preferences. Applying this framework to chronic obstructive pulmonary disease pharmacotherapy resulted in a stakeholder-informed treatment threshold that was substantially lower than the implicit thresholds in contemporary guidelines.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Sadatsafavi M, Khakban A, Mohammadi T, et al. Stakeholder-informed positivity thresholds for disease markers and risk scores: a methodological framework and an application in obstructive lung disease. J Clin Epidemiol. 2024. PMID: 39218236. doi:10.1016/j.jclinepi.2024.111509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。